Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Influence Of Protamine Shell On Nanoemulsions As A Carrier For Cyclosporine-A Skin Delivery

M. J. Alvarez-Figueroa, José María Abarca-Riquelme, J. V. González-Aramundiz
Published 2019 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Abstract Novel protamine-based nanosystems have been studied for cyclosporine-A (CsA) skin delivery. Core-shell structure systems have been developed to this end. These vehicles have particles sizes of 200–300 nm, a low polydispersity index and a zeta potential which varies between −16 mV and +35 mV. The resulting four nanosystems efficiently encapsulated CsA in their oily nucleus (60–80%) and released this drug in a controlled manner. These formulations have shown a high stability in aqueous suspension in storage conditions at 4 °C (for at least 21 months) and in acetate buffer at a physiological temperature of 37 °C (for at least 24 h). Ex vivo transdermal diffusion experiments using Franz diffusion cells and 2- to 3-day-old pig skin as a biological barrier were performed. All nanoformulations designed produced an increase in CsA transdermal delivery and two of these nanosystems presented a marked promoting effect; the more relevant parameters were smaller particle size (200 ± 7 nm) and negative superficial charge. Finally, the ability of these nanosystems to enhance retention of CsA in the skin was also studied. The protamine disposition in the shell influenced CsA skin retention. Therefore, the incorporation of CsA into the nanosystems studied here makes them suitable vehicles for CsA transdermal administration. Graphical Abstract
This paper references
10.3389/fimmu.2018.00791
Polymeric Nanocapsules for Vaccine Delivery: Influence of the Polymeric Shell on the Interaction With the Immune System
Mercedes Peleteiro (2018)
10.1016/S0378-5173(99)00361-0
Lecithin vesicular carriers for transdermal delivery of cyclosporin A.
J. Guo (2000)
10.1007/s11051-013-1515-7
Polyarginine nanocapsules: a new platform for intracellular drug delivery
M. V. Lozano (2013)
10.1016/j.ijpharm.2011.03.049
Liposome surface charge influence on skin penetration behaviour.
A. Gillet (2011)
10.1016/j.jconrel.2013.08.006
Stability of nanosuspensions in drug delivery.
Y. Wang (2013)
Size-dependent penetration of nanoemulsions
Y Li (2017)
10.2174/1566523217666170510151540
Recent Advances in Skin Penetration Enhancers for Transdermal Gene and Drug Delivery.
Morteza Amjadi (2017)
10.1016/j.jconrel.2014.11.015
Topical delivery of Cyclosporine A into the skin using SPACE-peptide.
Ming Chen (2015)
10.18632/oncotarget.17130
Size-dependent penetration of nanoemulsions into epidermis and hair follicles: implications for transdermal delivery and immunization
R. Su (2017)
10.1021/BC0501451
Protamine as an efficient membrane-translocating peptide.
F. Reynolds (2005)
10.1016/j.jconrel.2016.11.012
Rational design of protamine nanocapsules as antigen delivery carriers
J. V. González-Aramundiz (2017)
10.1016/S1382-6689(00)00035-1
Percutaneous penetration studies for risk assessment.
Sartorelli (2000)
10.1016/j.ijpharm.2010.10.008
Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution.
Jie Shen (2010)
10.1016/j.jconrel.2009.10.016
Nanotechnology and the transdermal route: A state of the art review and critical appraisal.
G. Cevc (2010)
10.1111/j.2042-7158.1991.tb06688.x
Unusual solubility behaviour of cyclosporin A in aqueous media
G. Ismailos (1991)
10.1016/j.ejps.2015.02.018
In vitro skin models as a tool in optimization of drug formulation.
G. E. Flaten (2015)
10.1039/9781849735292-00303
Chapter 6.1:Physiological and Mechanistic Issues of the Skin Barrier
M. J. Alvarez-Figueroa (2012)
10.1002/jps.23282
Surface-charge-dependent nanoparticles accumulation in inflamed skin.
Mona M A Abdel-Mottaleb (2012)
10.1111/j.1600-0846.2006.00179.x
Porcine ear skin: an in vitro model for human skin
U. Jacobi (2007)
10.1211/jpp.60.2.0002
In‐vitro permeation of drugs into porcine hair follicles: is it quantitatively equivalent to permeation into human hair follicles?
Yakov Frum (2008)
10.1016/j.ejps.2017.06.025
Comparison of liposomal drug formulations for transdermal iontophoretic drug delivery
K. Malinovskaja-Gomez (2017)
10.1016/j.colsurfb.2011.03.020
Development and characterization of nanocapsules comprising dodecyltrimethylammonium chloride and κ-carrageenan.
A. Rosas-Durazo (2011)
10.1016/j.jaad.2010.02.063
The use of cyclosporine in dermatology: part I.
Karrie T Amor (2010)
10.1016/j.yrtph.2015.05.005
Nanoparticles skin absorption: New aspects for a safety profile evaluation.
F. Larese Filon (2015)
10.1016/j.ijpharm.2018.02.044
Transdermal delivery of raloxifene HCl via ethosomal system: Formulation, advanced characterizations and pharmacokinetic evaluation
S. Mahmood (2018)
10.1021/acs.langmuir.7b01815
Influence of Protamine Functionalization on the Colloidal Stability of 1D and 2D Titanium Oxide Nanostructures.
Paul Rouster (2017)
10.1002/LSM.20283
Management of injected hyaluronic acid induced Tyndall effects
R. Hirsch (2006)
10.1007/978-1-4939-2806-4_1
Classes of Cell-Penetrating Peptides.
M. Pooga (2015)
10.1016/J.EJPB.2004.12.003
Topical delivery of cyclosporin A: an in vitro study using monoolein as a penetration enhancer.
L. B. Lopes (2005)
10.1016/S0168-3659(98)00060-1
Methods for quantitative determination of drug localized in the skin.
E. Touitou (1998)
10.3390/nano8090659
Lower-Sized Chitosan Nanocapsules for Transcutaneous Antigen Delivery
Juan I. Bussio (2018)
10.1002/JPS.2600840512
Percutaneous absorption and dermal delivery of cyclosporin A.
H. Choi (1995)
10.2147/IJN.S157566
Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis
M. Naeem (2018)
10.1016/j.cis.2014.07.015
Aggregation kinetics and colloidal stability of functionalized nanoparticles.
F. Gambinossi (2015)
10.1038/srep45292
Effect of Size and Surface Charge of Gold Nanoparticles on their Skin Permeability: A Molecular Dynamics Study
R. Gupta (2017)
10.1016/j.jconrel.2016.10.002
The interaction of protamine nanocapsules with the intestinal epithelium: A mechanistic approach.
Lungile Nomcebo Thwala (2016)
10.1016/J.IJPHARM.2003.10.038
Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge.
A. Kohli (2004)
Development and characterization of nanocapsules comprising dodecyltrimethylammonium chloride and j-carrageenan
A Rosas-Durazo (2011)
10.1016/j.chemphyslip.2014.11.004
Development characterization and skin permeating potential of lipid based novel delivery system for topical treatment of psoriasis.
M. Pradhan (2015)
10.1080/10837450.2018.1441302
Essential oils in niosomes for enhanced transdermal delivery of felodipine
Rania K Eid (2019)
10.1016/j.ejpb.2018.02.037
Delivery of oat‐derived phytoceramides into the stratum corneum of the skin using nanocarriers: Formulation, characterization and in vitro and ex‐vivo penetration studies
Efrem N. Tessema (2018)
10.2174/156720105774370168
Lipid-protamine-DNA-mediated antigen delivery.
D. P. Vangasseri (2005)
10.1016/J.IJPHARM.2004.01.016
Iontophoresis of lecithin vesicles of cyclosporin A.
R. Boinpally (2004)
10.1517/17425247.2014.875528
Skin permeabilization for transdermal drug delivery: recent advances and future prospects
Carl M Schoellhammer (2014)
Preparation and characterization of solid lipid
Z Urb an-Morl an (2010)
10.1002/jat.3476
Potential applications and human biosafety of nanomaterials used in nanomedicine
H. Su (2018)
drug delivery and drug targeting
CM Schoellhammer (2014)
10.1016/j.jchromb.2013.02.001
Ultra high performance liquid chromatography-tandem mass spectrometry method for cyclosporine a quantification in biological samples and lipid nanosystems.
M. Guada (2013)
10.1016/j.drudis.2017.08.001
Tocotrienols: the unsaturated sidekick shifting new paradigms in vitamin E therapeutics.
M. M. Kanchi (2017)
10.1007/s13346-016-0312-0
Polymeric nanocapsules: a potential new therapy for corneal wound healing
S. Reimondez-Troitiño (2016)
10.1016/j.ijpharm.2017.07.044
Formulations and toxicologic in vivo studies of aqueous cyclosporin A eye drops with cyclodextrin nanoparticles.
S. Jóhannsdóttir (2017)
10.1134/S000629791112011X
Cell-penetrating peptides. Methods and protocols
G. Wiederschain (2011)
10.2147/IJN.S12125
Preparation and characterization of solid lipid nanoparticles containing cyclosporine by the emulsification-diffusion method
Z. Urbán-Morlán (2010)
10.1021/acsnano.6b06040
Diverse Applications of Nanomedicine
B. Pelaz (2017)
10.1021/acs.molpharmaceut.8b00852
Protamine Nanocapsules for the Development of Thermostable Adjuvanted Nanovaccines.
J. V. González-Aramundiz (2018)
10.1080/10837450802088505
Passive and Iontophoretic Transdermal Penetration of Chlorpromazine
M. J. Alvarez-Figueroa (2008)
10.1016/j.jid.2017.07.828
New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis.
J. Roujeau (2017)
10.1016/j.ejps.2015.04.009
Protamine-oligonucleotide-nanoparticles: Recent advances in drug delivery and drug targeting.
B. Scheicher (2015)
10.1016/j.ijpharm.2015.02.028
Enhanced in vivo therapeutic efficacy of plitidepsin-loaded nanocapsules decorated with a new poly-aminoacid-PEG derivative.
G. Lollo (2015)
10.1080/10837450802088505
Passive and iontophoretic transdermal penetration of chlorpromazine.
M. J. Alvarez-figueroa (2008)
10.1081/DIS-100102675
Ostwald Ripening and Related Phenomena
A. Kabalnov (2001)
10.1691/PH.2009.8373
Topical administration of cyclosporin A in a solid lipid nanoparticle formulation.
S. Kim (2009)
10.1016/s0021-9258(18)73958-6
THE PROTAMINE SALTS OF PHOSPHATIDES, WITH REMARKS ON THE PROBLEM OF LIPOPROTEINS
E. Chargaff (1938)
10.1016/S0168-3659(97)00168-5
In vitro percutaneous absorption enhancement of a lipophilic drug tamoxifen by terpenes.
S. Gao (1998)
10.1016/J.IJPHARM.2006.07.022
Investigation into the potential of low-frequency ultrasound facilitated topical delivery of Cyclosporin A.
Hongzhuo Liu (2006)
Development and Characterization
M. Hebsur (1998)
10.2147/CPAA.S64788
Skin models for the testing of transdermal drugs
E. Abd (2016)
Expert Opin Drug Deliv
J Shen (2010)
10.1016/j.jconrel.2011.12.039
Towards tailored vaccine delivery: needs, challenges and perspectives.
Jean-Pierre Amorij (2012)
10.2174/092986611795713989
Protamines: structural complexity, evolution and chromatin patterning.
H. Kasinsky (2011)
10.1016/j.ejpb.2015.09.019
Protamine-based nanoparticles as new antigen delivery systems.
J. V. González-Aramundiz (2015)
10.1016/j.jaad.2010.02.062
The use of cyclosporine in dermatology: part II.
C. Ryan (2010)
In Vitro, ex vivo, and in vivo evaluation of a dual pH/redox responsive nanoliposomal sludge for transdermal drug delivery
S Mavuso (2018)
10.1517/17425247.2012.647906
Polypeptides and polyaminoacids in drug delivery
J. V. González-Aramundiz (2012)
10.1016/j.biotechadv.2011.03.004
Cyclosporin A--a review on fermentative production, downstream processing and pharmacological applications.
S. Survase (2011)
10.1111/bph.13059
Transdermal patches: history, development and pharmacology
M. N. Pastore (2015)
10.1371/journal.pone.0092978
Microfluidic-Enabled Liposomes Elucidate Size-Dependent Transdermal Transport
R. R. Hood (2014)
10.1016/j.ijpharm.2010.08.007
Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach.
S. Onoue (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar